Leukemia

Articles

Results of the phase 1 portion of ZUMA-4 support continued investigation into the efficacy of KTE-X19 in pediatric patients with B-cell acute lymphoblastic leukemia.

KTE-X19 Safe, Efficacious as Therapy for Pediatric B-Cell ALL in ZUMA-4

Data presented at 2021 ASCO indicated that chimeric antigen receptor therapy with ALLO-501A plus ALLO-647 lymphodepletion showed promise in patients with relapsed/refractory large B-cell lymphoma. 

Allogeneic CAR T-Cell Therapy in R/R Large B-Cell Lymphoma Demonstrates Efficacy Signals

Successful treatment of patients with Philadelphia chromosome–positive acute lymphocytic leukemia was noted with ponatinib plus blinatumomab, denoted by complete and major molecular responses.

HSCT-Sparing, Chemotherapy-Free Treatment of Ph+ ALL With Ponatinib/Blinatumomab Leads to 100% CR Rate

Reducing caloric and nutrient intake for patients who were overweight or obese and undergoing induction for B-cell acute lymphoblastic leukemia was feasible and improved patient response, according to an early-phase trial.

Caloric and Nutrient Restrictions Positively Impacted Response for Overweight Patients With B-cell ALL

Data in the Journal of Clinical Oncology found that low-intensity chemotherapy without additional intensified pegaspargase cured almost all patients treated on the Children’s Oncology Group AALL0331 trial.

Low-Intensity Chemotherapy Without Intensified Pegaspargase Cured Most Patients With Low-Risk B-ALL

CD19-directed CAR T-cell therapy brexucabtagene autoleucel will be considered by FDA for indication in adults with B-cell precursor acute lymphoblastic leukemia.

Application for Brexucabtagene Autoleucel in B-cell ALL Submitted to FDA for Consideration

A study conducted across 20 medical centers and hospitals in China concluded that treatment timing, total intravenous anesthesia, and flow cytometry were associated with a reduced risk of central nervous system relapse for pediatric patients with acute lymphoblastic leukemia.

Treatment Timing and Other Prognostic Factors Associated With Reduction in CNS Relapse Risk for Pediatric ALL

Follow-up of 4.8 years to a phase 1 trial demonstrated that deep and durable responses are attainable in a large cohort of children and young adult patients with B-cell acute lymphoblastic leukemia who were treated with CD19-directed CAR T-cell therapy followed by allogeneic hematopoietic stem cell transplantation.

Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL

Children, adolescents, and young adult patients in first B-cell acute lymphoblastic leukemia relapse did not experience a statistically significant disease-free survival benefit with blinatumomab treatment compared with chemotherapy.

No Disease-Free Survival Benefit Seen When Comparing Blinatumomab With Chemotherapy for Young Patients with B-ALL

In this study, investigators sough to determine the incidence of CRLF2 rearrangements and IKZF1 deletions in Hispanic versus non-Hispanic children with B-cell acute lymphoblastic leukemia.

Acute Lymphoblastic Leukemia | Topics